Alterity Therapeutics (ATH) Stock Overview
Engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
ATH Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Alterity Therapeutics Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.01 |
| 52 Week High | AU$0.019 |
| 52 Week Low | AU$0.002 |
| Beta | 0.32 |
| 1 Month Change | -23.08% |
| 3 Month Change | 0% |
| 1 Year Change | 150.00% |
| 3 Year Change | -25.93% |
| 5 Year Change | -80.00% |
| Change since IPO | -99.02% |
Recent News & Updates
Recent updates
We Think Alterity Therapeutics (ASX:ATH) Can Easily Afford To Drive Business Growth
Aug 31
Shareholders May Be More Conservative With Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation For Now
Nov 23We're Keeping An Eye On Alterity Therapeutics' (ASX:ATH) Cash Burn Rate
Jun 28Is Alterity Therapeutics (ASX:ATH) In A Good Position To Invest In Growth?
Mar 07We're Hopeful That Alterity Therapeutics (ASX:ATH) Will Use Its Cash Wisely
May 16Here's Why We're Watching Alterity Therapeutics' (ASX:ATH) Cash Burn Situation
Jan 31How Much Is Alterity Therapeutics Limited (ASX:ATH) CEO Getting Paid?
Dec 09Shareholder Returns
| ATH | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 5.3% | 7.2% | 2.3% |
| 1Y | 150.0% | -25.7% | 10.1% |
Return vs Industry: ATH exceeded the Australian Biotechs industry which returned -26.2% over the past year.
Return vs Market: ATH exceeded the Australian Market which returned 8.8% over the past year.
Price Volatility
| ATH volatility | |
|---|---|
| ATH Average Weekly Movement | 25.9% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 9.3% |
| 10% most volatile stocks in AU Market | 19.7% |
| 10% least volatile stocks in AU Market | 3.4% |
Stable Share Price: ATH's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: ATH's weekly volatility has decreased from 31% to 26% over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 9 | David Stamler | alteritytherapeutics.com |
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy.
Alterity Therapeutics Limited Fundamentals Summary
| ATH fundamental statistics | |
|---|---|
| Market cap | AU$108.75m |
| Earnings (TTM) | -AU$12.15m |
| Revenue (TTM) | AU$5.44m |
Is ATH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ATH income statement (TTM) | |
|---|---|
| Revenue | AU$5.44m |
| Cost of Revenue | AU$127.52k |
| Gross Profit | AU$5.31m |
| Other Expenses | AU$17.46m |
| Earnings | -AU$12.15m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0011 |
| Gross Margin | 97.66% |
| Net Profit Margin | -223.35% |
| Debt/Equity Ratio | 0% |
How did ATH perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 08:38 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alterity Therapeutics Limited is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| George Zavoico | B. Riley Securities, Inc. |
| Vernon Bernardino | FBR Capital Markets & Co. |
| Aydin Huseynov | Ladenburg Thalmann & Company |